Acquired Company
Xeno Acquisition Corp., a wholly owned subsidiary of XenoTherapeutics, completed the acquisition of ESSA Pharma on 10/9/2025 for approximately $0.1242 per share, plus one contingent value right per share.
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company was incorporated in 2009 and is headquartered in Vancouver, Canada. As of October 9, 2025, ESSA Pharma Inc. operates as a subsidiary of Alexis Bio, Inc. Show more
999 West Broadway, Vancouver, BC, V5Z 1K5, Canada
Start AI Chat
Market Cap
9.518M
52 Wk Range
$0.18 - $5.97
Previous Close
$0.20
Open
$0.20
Volume
N/A
Day Range
$0.20 - $0.20
Enterprise Value
-99.33M
Cash
109.6M
Avg Qtr Burn
-5.221M
Insider Ownership
5.62%
Institutional Own.
73.70%
Qtr Updated
06/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Masofaniten (EPI-7386) (antiandrogen) + apalutamide and abiraterone acetate Details Cancer, Prostate cancer | Failed Discontinued | |
Masofaniten (EPI-7386) (antiandrogen) Monotherapy Details Castration-resistant prostate cancer | Failed Discontinued | |
Masofaniten (EPI-7386) (antiandrogen) combo w/ enzalutamide Details Prostate cancer, Cancer | Failed Discontinued |